key: cord-0829039-0fn7gy48 authors: Pillai, Krishna; Mekkawy, Ahmed H.; Akhter, Javed; Valle, Sarah J.; Morris, David L. title: Effect of nebulised BromAc® on rheology of artificial sputum: relevance to muco-obstructive respiratory diseases including COVID-19 date: 2021-12-28 journal: bioRxiv DOI: 10.1101/2021.12.28.474344 sha: b765103e4011bb33014f52638f88d7471231e4b9 doc_id: 829039 cord_uid: 0fn7gy48 Respiratory diseases such as cystic fibrosis, COPD, bronchiectasis asthma and COVID-19 are difficult to treat owing to viscous secretions in the airways that evade mucocilliary clearance. Since earlier studies have shown success with BromAc® as mucolytic agent for treating a rare disease known as pseudomyxoma peritonei (PMP), we tested the formulation on two gelatinous airway representative sputa models, in order to determine whether similar efficacy exist. The sputum (1.5 ml) lodged in an endotracheal tube was treated to aerosolised N-acetylcysteine, bromelain, or their combination (BromAc®) using a nebuliser with 6.0 ml of the agents in phosphate buffer saline, over 25 min. Controls received phosphate buffer saline. The dynamic viscosity was measured before and after treatment using a capillary tube method, whilst the sputum flow (ml/sec) was assessed using a 0.5 ml pipette. Finally, the sequestered agents (concentration) in the sputa after treatment were quantified using standard bromelain and N-acetylcysteine chromogenic assays. Results indicated that bromelain and N-acetylcysteine affected both the dynamic viscosities and pipette flow in the two sputa models, with changes in the former parameter having immense effect on the latter. BromAc® showed a greater rheological effect on both the sputa models compared to individual agents. Further, correlation was found between the rheological effects and the concentration of agents in the sputa. Hence, this study indicates that BromAc® may be used as a successful mucolytic for clearing airway congestion caused by thick mucinous immobile secretion, however further studies with patient sputum samples using aerosol BromAc® is warranted. In the healthy state, secretions in the respiratory tract are continuously cleared by the cilia lining the air passages and expectorated as sputum. However, this is both dependent on the constituency and rheology of the secretion which affects ciliary clearance [1, 2] . Viscosity in the range 12-15 Pa and an elastic modulus of 1 Pa are necessary for optimal mucocilliary clearance [3, 4] Since the airways are continuously exposed to dust particles, pathogens and other exogenous molecules, the secretion propelled by ciliary motion serves to expel these harmful molecules continuously [5] and any disruption may result in accumulation leading to respiratory infection, pneumonia etc. [6] . In cystic fibrosis, a genetic disorder of the CFTR (cystic fibrosis transmembrane conductance receptor) gene, thick mucinous secretion accumulates in the respiratory tract resulting in mucus plugging, bacterial infection and progressive deterioration in lung function [7] . A similar accumulation of mucinous secretion with bacterial infection may result in chronic obstructive pulmonary disease (COPD) and other respiratory infectious diseases [8] . In fatal asthma, airway plugging inevitably with mucus-rich sputum is almost seen [9] . Hence, stasis of airways mucus secretion may lead to a variety of respiratory disorders. Normal airway secretion is composed of mucins (MUC5B and MUC 5AC), water, sodium chloride, bicarbonate, and cellular materials with a pH of 7.0 [10] [11] [12] . The mucins serve as a protective barrier for the epithelial cells lining the respiratory tract as well as tissues beneath. In a diseased state, such as bacterial infection, owing to inflammation excess mucin is secreted by the goblet cells as a protective measure with infiltrating white blood cells [13] , accumulation of DNA fragments from dead cells and other solids along with sodium, chloride and bicarbonate imbalance [14] that results in loss of water with the secretion becoming thick and purulent (bacterial infection) that eventuates in the reduction or absence of ciliary clearance [15] . Acidic pH in cystic fibrosis sputum as reported in some studies [16] , may encourage the cross linking of DNA, mucins and cellular fragments with additional milieu for bacterial growth and sputum stasis [17] . Recent studies have shown a great similarity between the respiratory secretions of COVID-19 patients and cystic fibrosis (CF) indicating that successful treatment to mobilise the sputum in CF may be used for treating COVID-19 [18] Elevated Muc1 and Muc5AC are seen in COVID-19 sputum [19] . Mucus production stimulated by IFN-AhR signalling triggers hypoxia in a mouse model of COVID-19 [20] . Lower airway viscous secretions in COVID-19 lead to the requirement for a high inspiratory plateau pressure, which required suction pressure of 20 KPa causing closure of distal airways [21] . Stickiness of sputum in associated with more severe disease in COVID-19 patients [22] . Cytokine storm and sudden mucus hypersecretion is well understood to be an important part of COVID-19 for which one drug is inadequate [23] . Further elevated levels of solids including proteins, hyaluronic acid, double stranded DNA (dsDNA) and infiltrating cells along with bacterial colonization was observed in both the diseases as compared to normal sputum, without significant changes in pH (7) (8) although some studies on CF have shown a depressed pH [15] . Elevated level of solids has also been shown to have a considerable effect on the rheology of the secretion and hence its clearance. Noticeably, the concentration of double stranded (dsDNA) is much higher (about 600 µg/ml) as compared to hyaluronic acid (about 7.0 µg/ml) in COVID-19 lung secretion suggesting that dsDNA may have a higher impact on the rheology of the secretion. Treatment options to enhance the clearance of stagnating sputa in CF is through rehydration using saline [24] , agents such as Acetylcysteine (NAC), L-cystine, cysteamine and other pharmaceutical agents that are mucolytics [25] [26] [27] together with additional antimicrobial agents when there is infection [28] . In diseases such as cystic fibrosis, if stasis of the secretion in the respiratory tract can be halted or modulated, then the invasion of microbes may be reduced or avoided [29] . Similarly in diseases such as pneumonia, COPD and CF, the prevention of muco-ciliary stasis may enable the prevention of microbial invasion since stasis leads to accumulation of foreign agents including microbes. Prevention of respiratory secretion stasis in COVID-19 may prevent deterioration in lung function, transplantation, and death. Stasis of thick pulmonary secretions prevents oxygenation with rapid respiratory failure in COVID-19 patients [22, 30] . Further, with current development of various therapeutic agents for nasal delivery or through the respiratory route, clear airway passages are a requirement for such treatment. BromAc ® , a combination of Bromelain and Acetylcysteine has shown both anticancer and mucolytic properties [31] [32] [33] and is currently undergoing phase 2 clinical evaluation for the treatment of pseudomyxoma peritonei (PMP) where cancer cells secrete copious amounts of mucin in the peritoneal cavity that eventually restricts nutritional intake resulting in death [34] . Since both the agents in BromAc ® possess mucolytic properties, demonstrate synergy [33] , and have antimicrobial properties [35, 36] they may serve in both solubilization of mucinous secretion whilst also acting as an anti-microbial agent. Owing to BromAc ® 's strong mucolytic activity, with its hydrolytic action on peptide and glycosidic bonds along with its disulfide reductive properties [37, 38] it is envisaged that these two agents may solubilize dense and purulent sputa secreted in the airways in disease states. Preliminary studies with BromAc ® on cystic fibrosis sputa has shown that it clearly disintegrates the sticky mucinous mass into a free-flowing solution in vitro (unpublished data) and hence in the current study we investigate the mucolytic effect of nebulised BromAc ® on two sputa models since we envisage using this formulation in aerosol form for treatment. The two sputa models used in this study are artificial sputa (AS) as well as simulated sputa (SS) that is mucinous secretion from PMP patients which has been specially treated to represent thick airway sputa. Nebulised delivery of therapeutics is a convenient method for treating diseases of the airways [39] . For preparing artificial sputa the following materials were purchased from Sigma Aldrich, Sydney, Australia: Porcine mucin, Salmon sperm DNA, potassium chloride, sodium chloride, Trizma ® base. TPTZ [2,4,6-Tris(2-pyridyl)-s-triazine], Ferrous chloride. PMP mucin of soft grade was obtained from a clinical sample that had been assessed for its softness index [40] . Pipettes (0.5 ml), capillary tubes, endotracheal tubes size 9.0, Nebulizer equipment (Philips Respironics InnoSpire Elegance Compressor, flow rate 7 L/min, 10 psi). Artificial sputum was prepared following protocol as detailed by Kirchner [41] . Briefly, 250 mg of porcine mucin, 200 mg of sperm DNA, 295 mg of Diethylene Triamine Penta-Acetic Acid (DTPA), 25 mg sodium chloride, 110 mg potassium chloride, 140 mg Tris base were mixed in a volume of 30 ml of distilled water and pH adjusted to 7.0 using Tris base. The volume of the solution was then adjusted to 35 ml. Further dilutions were then carried out to adjust viscosity as desired. Six grams of soft PMP mucin was homogenised using a shredder with phosphate buffer saline (PBS) (3.0 ml) with sonification and vortexed until a homogenous mixture was formed, with incubation at 37 o C to remove air bubbles and after which viscosity was adjusted (further dilutions with PBS). The pH was adjusted to 7.0 using either 1.0 M NaOH or 0.1 N Hydrochloric acid. Dynamic viscosity (γ) of sputum was measured using the capillary tube method as outlined by Santander and Castellano [42] . The dynamic viscosity of the sputa was measured before and after using the capillary tube method, whilst the pipette flow time was also measured as described earlier using a 0.5 ml glass pipette. Samples were equilibrated to 25 o C before measurement. A similar investigation as above was carried out to determine a comparative dynamic viscosity and pipette flow time. Similar treatment as in previous experiment for NAC, was carried out using Bromelain (125 and 250 µg/ml) in PBS (pH 7.0) along with control using PBS (pH 7.0). Both dynamic viscosity and pipette flow time was measured as outlined earlier for both artificial and PMP simulated sputa models. Using a combination of NAC (20 mg/ml) with either 125 or 250 µg/ml Bromelain in PBS (pH 7.0), a similar investigation was carried out as outlined earlier and measurements were made for both artificial and simulated sputa models. Suitable dilutions such as 1/5 and 1/10 of nebulised samples in PBS were carried out with subsequent filtration (0.44 um). To 250 µl of sample was added 250 µl of 1% azocaesin solution (prepared in distilled water). The samples were agitated at room temperature (25 o C) /1 hrs, after which 1.5 ml of 1% trichloroacetic acid was added, vortexed and centrifuged at 2500 RPM. To 150 µl of supernatant in a microwell was added an equal quantity of 0.5 M Sodium hydroxide solution and the OD at 410 nm was read using a spectrometer. A standard curve for Bromelain was generated following a similar procedure with Bromelain dilutions ranging from 200 µg/ml that was serially diluted. Suitable dilution such as 1/5 and 1/10 of aerosolised samples and filtration, as above was carried out. 10 mM solutions of TPTZ were prepared in distilled water (dH2O). Stock solution of NAC 10 mg/ml was prepared in PBS and pH adjusted to 7.0. Stock solution (10 mM) of Fe (III) was prepared in dH2O. The pH of all the reagents was adjusted to 7.0. To 125 µl of TPTZ was added 125 µl of Fe (III) solution vortex mixed and then followed by the addition of 100 µl of test solution. It was then vortexed and placed on a gentle shaker for 1 hour at ambient room temperature (25 o C) until full colour (blue) developed. 2.0 ml of dH2O was added, vortex mixed, and the OD was measured using aliquots of 200 µl in triplicates into a 96 well plate. Blanks only contained 100 µl of dH2O. The OD at 593 nm was read using UV spectrometer (Shimadzu). Suitable dilutions of Acetylcysteine ranging from 200 µg/ml down was prepared for the generation of standard curve. Table 1 shows the effect of aerosolised N-Acetylcysteine on both artificial and simulated sputa using two parametric measurements such as dynamic viscosity and pipette flow time. NAC: N-Acetylcysteine. ↓ = decrease; ↑= increase shows that in SS, the pipette flow is highly increased compared to control (PBS), after treatment with Bromelain. Table 5 Comparison of Dynamic viscosity (γ) and Flow speed (€) between the two sputa models when treated with Bromelain 125 or 250 µg/ml and in combination with NAC 20 mg/ml. Table 5 shows a comparison of D values (for both the dynamic viscosity (γ) and flow speed (€) between artificial sputa (AA) and simulated sputa (SS) treated with Bromelain only and with the addition of NAC 20 mg/ml. With the addition of NAC 20 mg/ml, there is a slight increase in (γ) in AS whilst the difference was much larger in SS model. Further, a similar trend in (€) was seen in both the sputa. Since, clearance of airway secretion, is mainly dependent on its rheological parameters, we decided to measure the dynamic viscosity (γ) and the flow speed (€) of the sputa before and after treatment with BromAc ® using two model sputa: artificial sputa (AS) and simulated sputa (SS), specially formulated to represent thick and static sputa. However, since two different agents (Bromelain and Acetylcysteine) are incorporated into the formulation (BromAc ® ), the effect of individual agents were first investigated with subsequent studies on their combination. The differences for both γ and € (pre-treated as opposed to treated) were calculated as a percentage denoted by D. Additionally, we also investigated the sequestration of Bromelain and NAC in the sputa before and after aerosol delivery for individual agents as well as their combinations since we wanted to correlate the concentrations of the agents within the sputa with the changes in rheological properties. Treatment of artificial sputa (AS) with aerosolised PBS indicated a minute drop in γ (0.65%) that may be mainly due to hydration, whilst in both the NAC 10 and 20 mg/ml, the reduction was by 6.0 and 10%, respectively. NAC is a well-known antioxidant and hence the reduction of disulfide linkages found in the protein and mucin components may be responsible for this change in viscosity [43, 44] . In comparison, simulated sputa (SS) in PBS showed a 2.0% drop in γ with substantial effect in NAC 10 and 20 mg/ml (γ =16 and 17%, respectively). This difference between both the sputa may be due to their differences in composition and variability of the constituents. The SS is mainly composed of mucinous mass that is heavily glycosylated with cellular debris and other components that may contain abundant disulfide linkages [45] and hence highly prone to the reductive action of NAC. Since the action of NAC is substantial in simulated sputa (SS) it may indicate that the percentage of disulfide linkages within the matrix may be much higher compared to artificial sputa (AS) (at NAC 20 mg/ml, γ was 17 and 10%, respectively). The effect on flow speed € was substantial (20% increase) with PBS treatment, indicating that hydration alone may have considerable effect on the viscoelastic property of sputum in AS which is agreement with other researchers on rheology of sputa [5, 46] . Further, at NAC 10 and 20 mg/ml, the effect was 28 and 40% respectively. In, comparison, the SS displayed a substantial increase in flow speed € with only PBS (12%) whilst both the NAC 10 and 20 mg/ml had a much higher impact (34 and 46% increase). The differences between the two sputa models in flow Dynamic viscosity (γ) and flow speed (€) on a comparable basis indicates that that both the sputa models were affected. The γ in SS was affected less by Bromelain as compared to AS and this may be due to their differences in composition, the former having a higher protein and glycosidic linkages compared to the latter. However, when treated in combination with NAC 20 mg/ml as compared to Bromelain alone, the effect on γ was higher in SS indicating that NAC may be playing a crucial role in reduction of disulfide bridges in the sample affecting the rheology of the sputum. On the other hand, when examining, €, both the sputa were well affected. There is a marked difference in € between Bromelain and that in combination with NAC indicating the importance of NAC in depolymerising the sputa. Importantly, these results further emphasise the high impact of these agents (Bromelain, NAC, BromAc ® ) on γ and € such that any slight increase of the former magnifies the latter. This finding is important particularly in developing formulas for improving the flow and clearance of sputum from the lungs. Although the effect of the individual agents and their combinations showed clearly that that they have substantial effect on both the sputa models with variable effects on the two parameters measured, the differences between the models observed may be mainly may be due to their heterogenous composition. The Artificial sputa was laboratory formulated containing mainly porcine mucin, DNA, and a number of other additives, that did not include hyaluronic acid found in cystic fibrosis and COVID-19 sputa. On the other hand, the simulated sputa (SS) contained a heavy load of mucinous materials which are substantially glycosylated (-O-linkages) that are prone to the enzymic action of Bromelain, whilst having a high load of cellular materials, lipids, sialic acid etc. in addition [45] . However, the observed rheological effects in these two model sputa may be sufficient to indicate that aerosol delivery of BromAc ® will have considerable effect on patient sputum from CF, COVID-19 or other sputum producing respiratory disease. Recent studies have indicated that Cystic fibrosis and COVID-19 airway secretion are heavily loaded with double stranded DNA (>600 µg/ml) and hyaluronic acid (7.0 µg/ml) [18] . In comparison the artificial sputa (AS) used in the present study contained about 5714 µg/ml DNA and 7142 µg/ml mucin. Hence, the variability in COVID-19 and CF sputum should not present any barrier to BromAc ® since Bromelain will hydrolyse the β-1-4 glycosidic linkages found in hyaluronic acid since it has been widely used in hydrolysis of chitosan, a complex heavily glycosylated glycoprotein [37] . In addition, earlier studies using cystic fibrosis sputa showed that BromAc ® reduced the thick sputum within the hour to a free-flowing liquid that used BromAc ® in solution instead of aerosol (unpublished data). Importantly, CF and COVID-19 sputa share very common chemical identity since they have similar composition [18] . Further, the SS model used in this study is heavily glycosylated with abundant glycosidic bonds and the mucolytic efficacy of BromAc ® in these sputa is a clear indication of its efficacy on chemical compounds containing the β1-4 glycosidic linkages that is found in hyaluronic acid. We and others see the potential of mucus targeting in COVID-19 [49] . Although the current study is very promising in the development of BromAc ® for application in CF and Barrier properties of mucus Collection and analysis of respiratory mucus from subjects without lung disease1-4 Rheological properties controlling mucociliary frequency and respiratory mucus transport Airway mucus function and dysfunction Effective mucus clearance is essential for respiratory health Bacterial lung infections in cystic fibrosis patients: an update Mucus, Microbiomes and Pulmonary Disease Autopsy and Imaging Studies of Mucus in Asthma. Lessons Learned about Disease Mechanisms and the Role of Mucus in Airflow Obstruction The normal trachea is cleaned by MUC5B mucin bundles from the submucosal glands coated with the MUC5AC mucin. Biochemical and biophysical research communications Mucus, mucins, and cystic fibrosis The biology of mucus: Composition, synthesis and organization. Advanced drug delivery reviews Lung macrophages drive mucus production and steroid-resistant inflammation in chronic bronchitis Cystic Fibrosis Lung Disease: An Overview Mucociliary clearance: pathophysiological aspects Acidic pH increases airway surface liquid viscosity in cystic fibrosis Reduced three-dimensional motility in dehydrated airway mucus prevents neutrophil capture and killing bacteria on airway epithelial surfaces Biochemical and Biophysical Characterization of Respiratory Secretions in Severe SARS-CoV-2 (COVID-19) Infections Elevated MUC1 and MUC5AC mucin protein levels in airway mucus of critical ill COVID-19 patients Mucus production stimulated by IFN-AhR signaling triggers hypoxia of COVID-19 Effects of the Lower Airway Secretions on Airway Opening Pressures and Suction Pressures in Critically Ill COVID-19 Patients: A Computational Simulation Sputum characteristics and airway clearance methods in patients with severe COVID-19 Cytokine Storm and Mucus Hypersecretion in COVID-19: Review of Mechanisms Nebulised hypertonic saline for cystic fibrosis Longterm treatment with oral N-acetylcysteine: affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial Cysteamine (Lynovex®), a novel mucoactive antimicrobial & antibiofilm agent for the treatment of cystic fibrosis New and Emerging Treatments for Cystic Fibrosis Cystic fibrosis microbiology: Advances in antimicrobial therapy COVID-19 and Respiratory System Disorders: Current Knowledge, Future Clinical and Translational Research Questions A formulation for in situ lysis of mucin secreted in pseudomyxoma peritonei Addition of bromelain and acetylcysteine to gemcitabine potentiates tumor inhibition in vivo in human colon cancer cell line LS174T Enhancing the potency of chemotherapeutic agents by combination with bromelain and Nacetylcysteine -an in vitro study with pancreatic and hepatic cancer cells A novel treatment of bromelain and acetylcysteine (BromAc) in patients with peritoneal mucinous tumours: A phase I first in man study Antibacterial effects of N-acetylcysteine against endodontic pathogens Reclamation of chitinous materials by bromelain for the preparation of antitumor and antifungal materials An Improved Inhaled Mucolytic to Treat Airway Muco-obstructive Diseases Inhaled Therapy in Respiratory Disease: The Complex Interplay of Pulmonary Kinetic Processes Efficacy of a novel mucolytic agent on pseudomyxoma peritonei mucin, with potential for treatment through peritoneal catheters Use of artificial sputum medium to test antibiotic efficacy against Pseudomonas aeruginosa in conditions more relevant to the cystic fibrosis lung Determination of the kinematic viscosity by the liquid rise in a capillary tube N-Acetylcysteine as an antioxidant and disulphide breaking agent: the reasons why Physical and chemical characteristics of mucin secreted by pseudomyxoma peritonei (PMP) Rheological analysis of sputum from patients with chronic bronchial diseases Numerical analysis of airway mucus clearance effectiveness using assisted coughing techniques N-acetylcysteine: antioxidant, aldehyde scavenger, and more Mucus targeting as a plausible approach to improve lung function in COVID-19 patients Mucpharm holds intellectual property of the use of BromAC ® for respiratory diseases. The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.